Albany International Earnings Call Transcripts
Fiscal Year 2026
-
A strategic review led to retaining the Salt Lake City facility and amending the CH-53K contract, improving profitability and reducing risk. Financial guidance was raised, with positive cash flow expected from 2027 and double-digit growth targeted for Engineered Composites.
-
Q2 2026 saw 5.8% revenue growth, record Engineered Composites results, and strong margins despite Machine Clothing softness from equipment downtime and lower Americas demand. Strategic review of Salt Lake City is on track, with robust aerospace and defense momentum.
-
The company is executing a focused strategy, emphasizing core weaving and material science capabilities to drive growth in aerospace, defense, and engineered fabrics. Recent wins, operational improvements, and disciplined capital allocation position it for margin expansion and innovation-led growth.
-
Revenue grew 7.8% year-over-year to $311 million, led by Engineered Composites, while Machine Clothing stabilized outside Asia. Q2 revenue is forecasted at $335–$345 million, with continued growth expected in composites and a cautious outlook for China.
-
Q4 AEC revenue was strong due to program performance and material pull forward, but future quarters will normalize. The Salt Lake City divestiture is a top priority, with AEC margins expected to rise post-transition. MC business remains stable, and 3D weaving is a key growth driver.
Fiscal Year 2025
-
Q4 2025 saw a 12% revenue increase to $321.2M, led by Engineered Composites growth, while Machine Clothing faced ongoing weakness in China. Strategic review of the Salt Lake City facility continues, and strong capital returns and innovation investments position the company for further growth.
-
Q3 results reflect a strategic shift, with a $147M loss reserve for CH-53K and exit from low-margin programs. Core machine clothing and engineered composites remain strong, but revenue and margins declined year-over-year. Guidance withdrawn pending strategic review update.
-
Second quarter results were below expectations due to operational disruptions and market softness, but a stronger second half is anticipated with ramp-ups in key aerospace and defense programs. Full-year guidance is reaffirmed, supported by ongoing operational improvements and new program growth.
-
The business leverages core weaving and material science expertise across machine clothing and aerospace, with strong growth in aerospace driven by unique 3D weaving technology and expanding defense programs. Margin expansion is supported by successful integration of acquisitions and operational improvements.
-
First quarter 2025 results met expectations with $289M revenue and strong operational execution. Heimbach integration and AEC backlog support a positive outlook, with full-year guidance reaffirmed and stronger performance expected in the second half.
Fiscal Year 2024
-
Record annual revenues and strong cash flow were achieved, despite Q4 headwinds from AEC adjustments and lower LEAP volumes. 2025 guidance anticipates modest growth, improved margins, and continued capital returns, with integration and operational improvements positioning both segments for long-term growth.
-
Net sales rose 6.1% year-over-year to $298 million, with Machine Clothing driving growth and AEC impacted by EAC adjustments. Margins improved in Machine Clothing, while AEC faced near-term headwinds but is expected to recover. Guidance for 2024 was tightened, with a positive outlook for cash flow and backlog exceeding $1 billion.
-
Full-year guidance was revised downward due to challenges in key aerospace programs, with AEC facing higher costs and production inefficiencies. Despite these headwinds, strong backlogs, leadership changes, and ongoing R&D investments support future growth.
-
Q2 2024 saw 21% sales growth, strong free cash flow, and robust order intake, driven by Heimbach integration and aerospace/defense demand. Margins were pressured by ramp-up inefficiencies and LEAP volatility, but guidance is reaffirmed with expectations for margin improvement in H2.